TARRYTOWN, N.Y., May 2 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. will hold a teleconference to discuss its 2007 first quarter financial results on Friday, May 4, 2007, beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific). A replay of the call will be accessible approximately two hours following the end of the call and will be archived through June 4, 2007.
The live conference call dial-in number is: 1-800-811-8845 (U.S./Canada) 1-913-981-4905 (International) To access a replay of the call: 1-888-203-1112 (U.S./Canada) 1-719-457-0820 (International) Conference replay PIN number is: 9100469
Emisphere will simultaneously be webcasting this teleconference. To access the live broadcast in listen-only mode or the subsequently archived recording, please go to the Company’s website at http://www.emisphere.com.
Please visit the site at least five minutes prior to start time for instructions.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. Emisphere’s business strategy is to develop oral forms of injectable drugs, either alone or with corporate partners, by applying its proprietary eligen(R) technology to those drugs or licensing its eligen(R) technology to partners who typically apply it directly to their marketed drugs. Emisphere’s eligen(R) technology has enabled the oral delivery of proteins, peptides, macromolecules and charged organics. Emisphere and its partners have advanced oral formulations or prototypes of salmon calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with world-leading pharmaceutical companies. For further information, please visit the Emisphere website, http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere’s product candidates and the sufficiency of Emisphere’s cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere’s drug delivery technology, Emisphere’s ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere’s filings with the Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in Emisphere’s (Commission File no. 1-10615) Annual Report on Form 10-K (File 000-17758) filed on March 6, 2007.
Emisphere Technologies, Inc.
CONTACT: Stewart Siskind of Emisphere Technologies, Inc., InvestorRelations, +1-914-785-4742, or media, Dan Budwick of BMC Communications,+1-212-477-9007 ext. 14
Web site: http://www.emisphere.com/
